Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ACADEMIA
ACADEMIA
- Opdivo Shows OS Rate of 62% in HCC at 12 Months: ASCO
June 1, 2015
- MHLW-Funded Study Calls for Use-Based Development Plans for Combination Drugs
May 7, 2015
- Six Deaths Confirmed through Tofacitinib PMS, Guidelines Not Followed in All Cases
April 30, 2015
- Biometric Society of Japan to Establish Certification System for Biostatisticians
April 17, 2015
- Study Group Recommends “Reference Groups,” Dose-Escalation Studies to Promote Development of Ultra-Orphan Drugs
April 8, 2015
- Medical University Association to Strengthen Collaboration with Industry
April 3, 2015
- Stop Use of SGLT-2 Inhibitors, NSAIDs in Elderly: Japan Geriatrics Society
April 3, 2015
- CRPC Drugs Xtandi, Zytiga Neck-and-Neck in Key Opinion Leader Poll
April 1, 2015
- New Stroke Guidelines to “Strongly Recommend” NOACs for NVAF
March 31, 2015
- Keytruda Demonstrates Superior OS, PFS to Yervoy in Advanced Melanoma in PIII Study: Merck
March 30, 2015
- Univ. of Tokyo to Provide Access to Comprehensive Database of Drug and Medical Device Seeds Starting in April
March 26, 2015
- Drug-Use Result Surveys Should Be Conducted in Elaborate Manner: Dr Narukawa
March 25, 2015
- Yervoy Extends Survival of Terminal Melanoma Patients, Same Might Hold True for Other Immunotherapies: Prof.
March 19, 2015
- Researcher Has High Hopes for Immunotherapies as Fourth Pillar of Cancer Treatment
March 17, 2015
- Large-Scale Genomic Screening Project Gets Underway to Make Gene Database of 4,500 Cancer Patients
March 12, 2015
- Urological Cancer Society to Be Inaugurated in October
March 12, 2015
- Interview on SGLT-2 Inhibitor Use (2): Prof. Watada Calls for Caution in Analyzing EPPV Data
March 9, 2015
- Interview on SGLT-2 Inhibitor Use (1): Prof. Ueki Says Flat Sales Reflect Cautious Prescribing by Physicians
March 6, 2015
- Astellas, Nagasaki Univ. Extend Joint Research Deal for Dengue Fever by 1 Year
March 3, 2015
- No Problems Found with Integrity of CASE-J Data Analyses: Kyoto Univ.
March 2, 2015
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…